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Abstract
Background: Interleukin-6 (IL-6) may have a protective role in acute liver disease but a detrimental effect in chronic liver
disease. It is unknown whether IL-6 is associated with risk of liver-related mortality in humans.
Aims: To determine if IL-6 is associated with an increased risk of all-cause, cardiovascular disease (CVD), cancer, and liver-
related mortality.
Methods: A prospective cohort study included 1843 participants who attended a research visit in 1984–87. Multiple
covariates were ascertained including serum IL-6. Multivariable-adjusted Cox proportional hazards regression analyses were
used to examine the association between serum IL-6 as a continuous (log transformed) variable with all-cause, CVD, cancer,
and liver-related mortality. Patients with prevalent CVD, cancer and liver disease were excluded for cause-specific mortality.
Results: The mean (6 standard deviation) age and body-mass-index (BMI) of participants was 68 (610.6) years and 25
(63.7) Kg/m
2, respectively. During the 25,802 person-years of follow-up, the cumulative all-cause, CVD, cancer, and liver-
related mortality were 53.1% (N=978), 25.5%, 11.3%, and 1.3%, respectively. The median (6IQR) length of follow-up was
15.3610.6 years. In multivariable analyses, adjusted for age, sex, alcohol, BMI, diabetes, hypertension, total cholesterol, HDL,
and smoking, one-SD increment in log-transformed serum IL-6 was associated with increased risk of all-cause, CVD, cancer,
and liver-related mortality, with hazard ratios of 1.48 (95% CI, 1.33–1.64), 1.38 (95% CI, 1.16–1.65), 1.35 (95% CI, 1.02–1.79),
and 1.88 (95% CI, 0.97–3.67), respectively. CRP adjustment attenuated the effects but the association between IL-6 and all-
cause and CVD mortality remained statistically significant, independent of CRP levels.
Conclusions: In community-dwelling older adults, serum IL-6 is associated with all-cause, CVD, cancer, and liver-related
mortality.
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Introduction
Interleukin-6 (IL-6) is a pleiotropic cytokine that has a
differential effect on tissue growth, repair, and regeneration [1–
3]. It may be essential for tissue regeneration in the acute setting,
but under certain conditions, prolonged exposure to IL-6 may
promote carcinogenesis [2]. Acute versus chronic exposure to IL-6
may have opposing effect on normal versus altered growth,
development and cell death [3]. During acute inflammation, IL-6
promotes the expansion and activation of T cells, initiates B cell
differentiation, regulates the liver production of acute phase
reactants such as C-reactive protein (CRP), and stimulates the
hypothalamic-pituitary-adrenal axis, which may be protective in
an acute setting [4]. However, prolonged exposure to IL-6 may
lead to activation of apoptosis, cell death and lower the threshold
for liver injury [3] Recent studies have shown that high serum IL-
6 levels increase the risk of cardiovascular disease (CVD) and
major coronary events [5–7]. In addition, high IL-6 mRNA
expression is found in atherosclerotic arteries of patients
undergoing heart transplantation and atherectomy [8]. In liver
disease, elevated IL-6 levels are seen in alcoholic cirrhosis, chronic
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and hepatocellular carcinoma (HCC) [9,10]. IL-6 expression also
correlates with disease severity in non-alcoholic fatty liver disease
(NAFLD) and is higher in nonalcoholic steatohepatitis (NASH)
than steatosis alone [11]. These findings suggest that IL-6 is
important in the pathogenesis and progression of cardiovascular
as well as chronic liver disease. Despite improved understanding
of IL-69s role in inflammation and chronic disease, there are
limited data on the effect of IL-6 on CVD, cancer, and liver-
related mortality in a large population-based cohort. In this study,
we investigate the predictive value of IL-6 levels for all-cause,
CVD, cancer, and liver-related mortality using a large, prospec-
tive cohort of older men and women in Southern California. We
hypothesized that 1.) Serum IL-6 is associated with an increased
risk of all-cause, CVD, cancer, and liver-related mortality in older
adults and 2.) The association between serum IL-6 and mortality
is independent of CRP levels.
Methods
Study Design and Population
The Rancho Bernardo Study (RBS) is a prospective cohort
study of older adults from a suburban Southern California
community. A total of 2480 adult residents from the original
cohort attended a clinical research examination between 1984 and
1987. This visit included a standardized questionnaire on medical
and medication history, alcohol consumption, smoking status, and
physical activity. Detailed information on the prevalence of CVD,
and other major chronic diseases along with objective measures of
disease severity were obtained. The details of the cohort, selection
criteria, and purpose of the RBS have been published previously
[12,13].
Ethics Statement
The institutional review board of the University of California,
San Diego approved the study protocol and a written informed
consent was obtained from all participants.
Exposure: Serum IL-6
IL-6 was measured in fasting serum samples using a high
sensitivity (0.094 pg/ml) commercial Elisa (Quantikine HS,
human IL-6 immunoassay; R&D Systems, Minneapolis, MN).
Mortality Follow-Up
Mortality status was determined by annual mailed question-
naires until December 31, 2005. Death certificates were obtained
from all decedents in this cohort; cause of death was classified by a
nosologist using the International Classification of Diseases (ICD),
Ninth Revision. Cancer deaths, CVD deaths, and deaths from all
causes included codes 140–239 (excluding 210–229), 390–459,
and 0–999 respectively. Liver deaths included underlying or
associated cause of death by codes 70.2–70.9, 155, 275.0–275.1,
571–573.
Covariate Assessment
Information for covariate analyses included age, sex, body mass
index (BMI), fasting serum total cholesterol and high-density
lipoprotein (HDL), fasting plasma glucose, measured blood
pressure, smoking status, alcohol use, and CRP levels. CRP was
measured using an automated, high-sensitivity immunonephelo-
metry method (sensitivity of 0.2 mg/liter, Dade Behring, Inc.,
Deerfield, IL). Participants had hypertension if they had an
average systolic blood pressure $140 mm Hg, diastolic blood
pressure $90, or were receiving anti-hypertensive medications.
Diabetes mellitus was defined as fasting plasma glucose $126 mg/
dl or treatment with either insulin or an oral hypoglycemic
medication. A current smoker or anyone who smoked 10 cigarettes
or more in the last year was classified as a smoker. Alcohol use
history including frequency, type, and quantity of alcoholic
beverages consumed in the past week was obtained. Alcohol was
considered as the number of alcoholic drinks (beer, wines, or
spirits) taken in a day, with one drink equivalent defined as either
12-ounces of beer or 8-ounces of malt liquor or 5-ounces of wine
or 1.5-ounces of a ‘‘shot’’ of 80-proof distilled spirits or liquor (e.g.,
gin, rum, vodka, or whiskey) according to the Centers for Disease
Control. Non-drinkers were defined as no alcohol use in the last
year.
Statistical Analysis
Descriptive statistics were used to compare the baseline
characteristics across tertiles of IL-6. Chi-square test was used to
examine the significance for trends from models with tertiles of IL-
6 concentration entered as an ordinal variable. We used the Cox
proportional hazards regression analysis to examine the hazards
ratio of all-cause, CVD, cancer, and liver-related mortality
associated with serum IL-6 levels as a continuous variable (IL-6
was log transformed to fulfill the conditions of normality for these
analyses) and also IL-6 divided into tertiles, with tertile 3 with
highest IL-6 and tertile 1 with lowest IL-6. We also performed a
hierarchical adjustment and examined the following models: 1)
age-sex adjusted, 2) multivariate model adjusted for age, sex,
alcohol, BMI, diabetes mellitus, systolic blood pressure, total
cholesterol, HDL, smoking, 3) Model 2 plus baseline CRP. IL-6
correlated significantly with CRP (Spearman correlation r
2=0.49,
p,0.001). BMI categories were as follows: BMI ,18.5 kg/m
2,
(normal BMI) 18.5–25 kg/m
2 as referent, BMI 25–30 kg/m
2, and
BMI $30 kg/m
2. Alcohol use was categorized as non-drinker, less
than median number of drinks, and greater than median number
of drinks as shown in table 1. Lastly, we performed all models
examining the association between serum IL-6 and CVD, cancer,
and liver-related mortality by excluding participants with preva-
lent CVD, cancer, or liver disease at baseline. Information on
prevalent CVD (including angina, myocardial infarction, cardiac
revascularization, stroke or transient ischemic attack, carotid
surgery, peripheral arterial surgery, and intermittent claudication
as previously reported) [14], cancer, and liver disease were
obtained by self-report, review of hospital admission records, and
questionnaires during baseline and annual follow-up mailers. We
also performed Wald test of interaction to examine the interaction
between IL-6 and age/sex for all the mortality outcomes. A two-
sided P-value ,0.05 was considered statistically significant. SAS
version 9.1 (SAS Institude, Cary, NC) was used for all analyses.
Results
Description of the Population
Baseline demographic, clinical, and laboratory characteristics of
the 1843 (55.8% women) participants are shown in Table 1. The
mean (6 standard deviation, SD) age and BMI was 68.4
(610.6) years and 25.0(63.7) kg/m
2, respectively. Participants
with high IL-6 levels (tertile 3=3.02–16.45 pg/ml) were signifi-
cantly older, more male, had higher BMI, SBP, triglycerides,
fasting plasma glucose, CRP levels, and were more likely to be
active smokers, diabetics as compared to participants with low IL-
6 levels (tertile 1=0.10–1.74 pg/ml). Participants with low IL-6
levels had higher total cholesterol and HDL compared to those
with high IL-6 levels.
IL-6 Predicts All-Cause and Liver Mortality
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During the 25,802 person-years of follow-up, the cumulative all-
cause, CVD, cancer, and liver-related mortality were (N=978)
53.1%, 25.5%, 11.3%, and 1.3%, respectively. The median
(6 IQR) length of follow-up was 15.3610.6 years. There were 23
deaths due to liver disease as an underlying cause of death with
only one death attributed to hepatocellular carcinoma (HCC).
Serum IL-6 as a Continuous Variable and Mortality Risk
All-cause Mortality. One standard deviation increment in
serum IL-6 was associated with 90% excess risk of all-cause
mortality (Table 2). In order to put the logarithmic scale into
clinical perspective, here, we provide an example to explain the
risk difference in IL-6 levels in pg/ml; the risk of mortality
increased by 90% when the IL-6 levels increased from 2.29 pg/ml
to 4.56 pg/ml (difference of 2.27 pg/ml, which is equivalent to the
standard deviation at the median). These results remained
statistically significant in age-sex adjusted, multivariable adjusted,
and multivariable with CRP adjusted models
CVD Mortality. Serum IL-6 was associated with a nearly
two-fold increased risk of CVD mortality. After exclusion of
participants with known CVD at baseline, serum IL-6 continued
to be a strongly associated with CVD mortality in the unadjusted,
age-sex adjusted, multivariable adjusted, and multivariable with
CRP adjusted models (Table 2).
Cancer Mortality. Serum IL-6 was associated with 74%
excess risk of cancer mortality after excluding participants with
cancer at baseline (Table 2). Results remained consistent serum
IL-6 associated with cancer mortality in unadjusted, age-sex
adjusted, and multivariable adjusted models (Table 2). However,
adjustment by CRP attenuated the association between IL-6 and
cancer mortality.
Liver Mortality. In unadjusted analysis, one log increment in
serum IL-6 was associated with a two-fold increased risk (HR 2.25,
95% CI 1.30–3.90) of liver-related mortality (data not shown).
These results persisted after adjusting for variables previously
shown to increase mortality in this population. CRP attenuated
the association between serum IL-6 and liver mortality. When
prevalent liver disease was excluded, serum IL-6 remained
significantly associated with liver-related mortality in unadjusted
(HR 2.28, 95% CI 1.27–4.10) and age-sex adjusted (HR 2.10,
95% CI 1.11–3.96) models only (Table 2).
Serum IL-6 Stratified Into Tertiles and Mortality Risk:
All-cause Mortality. When stratified into tertiles, high IL-6,
tertile 3, was significantly associated with all-cause mortality in
unadjusted (HR 2.99, 95% CI 2.54–3.53), age-sex adjusted,
Table 1. Baseline characteristics of participants based on tertiles of IL-6 in the Rancho Bernardo Study cohort.
N Total Sample Tertile 1 (N=615) Tertile 2 (N=615) Tertile 3 (N=613) P-Value (trend)
IL-6 Mean ± SD (pg/ml) 1.23 6 0.34 pg/ml 2.31 6 0.36 pg/ml 5.84 6 3.16 pg/ml
IL-6 Median ± IQR (pg/ml) 1843 2.27 6 2.16 pg/ml 1.29 6 0.48 pg/ml 2.27 6 0.62 pg/ml 4.53 6 3.25 pg/ml
Age, years (SD) 1843 68.4 (10.6) 64.0 (10.8) 69.5 (9.7) 71.5 (9.8) ,.0001
Women, n (%) 1843 1029(55.8) 394 (64.1) 317 (51.5) 318 (51.9) ,.0001
Body mass index (kg/m2) 1843
Mean, SD 25.0 (3.7) 24.2 (3.2) 25.3 (3.6) 25.5 (4.0) ,.0001
,18.5, n (%) 31 (1.7) 8 (1.3) 12 (2.0) 11 (1.8) ,.0001*
18.5 2,25, n (%) 965 (52.3) 378 (61.4) 304 (49.4) 283 (46.2)
25 2,30, n (%) 691 (37.5) 199 (32.4) 242 (39.3) 250 (40.8)
$30, n (%) 156 (8.5) 30 (4.9) 57 (9.3) 69 (11.2)
Alcohol use, n (%) 1843
None 678 (36.8) 224 (36.4) 210 (34.1) 244 (39.8) .0026*
, median drinks/day ** 552 (29.9) 192 (31.2) 212 (34.5) 148 (24.1)
$ median drinks/day 613 (33.3) 199 (32.4) 193 (31.4) 221 (36.1)
SBP (SD) 1841 137.4 (21.9) 130.4 (20.2) 137.8 (20.6) 144.1 (22.7) ,.0001
Hypertension, n (%) 1843 1314 (71.3) 354 (57.6) 458 (74.5) 502 (81.9) ,.0001
Lipid levels (SD)
Total cholesterol (mg/dl) 1843 220.2 (39.8) 224.3 (37.4) 220.2 (40.5) 216.0 (41.0) .0003
HDL (mg/dl) 1843 61.4 (18.7) 66.0 (18.5) 60.7 (18.0) 57.5 (18.6) ,.0001
Trig (mg/dl), geo mean (95% CI) 1843 103.0 (100.4–105.6) 91.5 (87.8–95.4) 105.3 (101.1–109.7) 113.3 (108.1–118.8) ,.0001
Total/HDL ratio 1843 3.9 (1.3) 3.6 (1.1) 3.9 (1.3) 4.1 (1.5) ,.0001
FPG mg/dl (SD) 1843 100.7 (20.3) 97.7 (17.2) 101.3 (20.0) 103.0 (23.1) ,.0001
Diabetes, n (%) 1843 253 (13.7) 43 (7.0) 93 (15.1) 117 (19.1) ,.0001
Current smoker, n (%) 1843 280 (15.2) 73 (11.9) 100 (16.3) 107 (17.5) .0064
CRP, geo mean (95% CI) 1792 1.8 (1.7–1.9) 1.0 (0.9–1.1) 1.7 (1.6–1.9) 3.6 (3.3–3.9) ,.0001
Abbreviations: SD; standard deviation, SBP; systolic blood pressure, HDL; high density lipoprotein, FPG; fasting plasma glucose, CRP; C-reactive protein, IL-6; interleukin-
6,
*Chi-square for association – can’t compute trend test, more than 2 rows.
**Median number of drinks/day among drinkers was 1.1.
doi:10.1371/journal.pone.0034218.t001
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models when compared to the two lowest combined or the lowest
IL-6 levels in tertile 1 (Table 3). In all models, serum IL-6 was
strongly associated with all-cause mortality independent of CRP
and all other covariates.
CVD Mortality. The association between IL-6 and CVD
mortality remained consistent between serum IL-6 stratified into
tertiles and CVD mortality in the unadjusted model with tertile 3
(HR 3.04, 95% CI 2.31–3.98) and tertile 2 (HR 1.69, 95% CI
1.26–2.25) versus tertile 1 (P value for trend ,0.0001, Table 3). In
all models, serum IL-6 was strongly associated with incident CVD
mortality independent of CRP and other covariates.
Cancer Mortality. In separate analyses using tertiles, high
IL-6 levels was associated with a statistically significant increased
risk of cancer mortality in unadjusted, and age-sex adjusted models
(Table 3). Multivariate-adjusted models were not significant the
association (Table 3).
Liver Mortality. When analyzed as tertiles, high IL-6 levels
was associated with increased risk of liver mortality but failed to
reach significance, likely reflecting limited power with only 23 (3
excluded due to prevalent liver disease at baseline) persons who
had liver-related mortality on their death certificates (Table 3).
Sensitivity Analysis: Wald test for interaction was utilized to
assess interaction between serum IL-6 levels and age (below and
above the median age of 70 years at baseline), and sex. There was
no interaction between serum Il-6 and age (interaction p-value of
0.2). However, the interaction between IL-6 and sex was
significant (interaction p-value ,0.002) but the hazards of
mortality did not differ in men versus women (p-value 0.5)
consistent with assumptions that serum Il-6 levels are higher in
men than women. There were no significant interactions between
any of the outcomes and sex/age (data not shown).
Discussion
Main Findings
In these community-dwelling older men and women with a
median follow-up of 15.3610.6 years, increased serum IL-6 levels
were associated with an increased risk of all-cause, CVD, cancer,
and liver-related mortality. After adjusting for age, sex, BMI, total
cholesterol, HDL, serum glucose, systolic blood pressure, smoking
status, and alcohol use, serum IL-6 remained independent risk
factor of all-cause, CVD, cancer, and liver-related mortality.
When CRP was added to our multivariable analyses, serum IL-6
was only associated with all-cause and CVD mortality, suggesting
a novel hypothesis that the association between IL-6 and cancer
and liver mortality is perhaps mediated via CRP-dependent
pathways whereas the association between IL-6 and CVD
mortality is not entirely dependent upon CRP. This remains to
be tested in future studies.
Table 2. The hazards associated with increased IL-6 and risk of all-cause, cardiovascular, cancer, and liver-related mortality in older
adults excluding individuals with prevalent CVD, cancer, and liver disease over 15 years of median follow-up.
N
Natural log-transformed
IL-6 HR (95% CI) P-value
All-cause Mortality No. of total deaths/total participants
Unadjusted 978/1843 1.90 (1.74–2.07) ,.0001
Age-sex adjusted 978/1843 1.53 (1.39–1.68) ,.0001
Multivariable adjusted 976/1841 1.48 (1.33–1.64) ,.0001
Multivariable+CRP adjusted 946/1790 1.39 (1.23–1.56) ,.0001
CVD Mortality (exclude individuals with
prevalent CVD; N=323 )
No. of CVD deaths/total participants
Unadjusted 329/1520 1.89 (1.64–2.19) ,.0001
Age-sex adjusted 329/1520 1.46 (1.23–1.72) ,.0001
Multivariable adjusted 329/1518 1.38 (1.16–1.65) .0004
Multivariable+CRP adjusted 319/1476 1.41 (1.15–1.72) .0009
Cancer Mortality (exclude individuals with
prevalent cancers; N=447)
No. of cancer deaths/total eligible participants
Unadjusted 134/1396 1.74 (1.37–2.20) ,.0001
Age-sex adjusted 134/1396 1.51 (1.17–1.96) .0017
Multivariable adjusted 134/1395 1.35 (1.02–1.79) .0343
Multivariable+CRP adjusted 130/1359 0.99 (0.71–1.38) .9400
Liver Disease Mortality (exclude individuals
with liver disease; N=52)
No. of liver deaths/total eligible participants
Unadjusted 20/1691 2.28 (1.27–4.10) .0058
Age-sex adjusted 20/1691 2.10 (1.11–3.96) .0218
Multivariable adjusted 20/1689 1.88 (0.97–3.67) .0633
Multivariable+CRP adjusted 20/1641 1.80 (0.84–3.85) .1277
HR; hazards ratio, CI; confidence interval.
statistically significant, a two-tailed p-value of less than 0.05 (bold).
Multivariate model includes: age, sex, alcohol, BMI, diabetes mellitus, systolic blood pressure, total chol, HDL, smoking.
Multivariate model+CRP includes: age, sex, alcohol, BMI, diabetes mellitus, systolic blood pressure, total chol, HDL, smoking, CRP.
doi:10.1371/journal.pone.0034218.t002
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literature
Several observational studies have examined the association
between serum IL-6 and mortality in older adults with conflicting
results. The Iowa 65+ Rural Health Study showed that high IL-6
levels were associated with a two-fold greater risk of all-cause
mortality in 1,293 elderly men and women [15]. In contrast, Arai
et al. reported that serum IL-6 was not associated with all-cause
mortality in 285 subjects with a mean age of 101.5 [16]. The
Vitality 90+ Study showed that serum IL-6 was not associated with
all-cause mortality [17]. More recently, the MEMO Study of 385
adults showed that serum IL-6 was an independent risk factor of
all-cause mortality in elderly men [18]. These conflicting findings
may be explained by the small samples size in several of these
studies, short follow-up periods, and higher age of the participants
suggesting survivor bias. Our population-based cohort study
enrolled a larger number of participants, had a longer mean
follow-up period, and a younger population compared to the
studies above. As a result, we were able to show a clear association
between serum IL-6 and all-cause mortality.
Although the association between IL-6, CVD, and CVD risk
factors such as diabetes has been recognized in previous cohorts,
few studies have examined the association between serum IL-6
and CVD mortality. Harris et al. reported that high IL-6 levels
were not an independent risk factor of CVD mortality in 1,293
elderly men and women [15]. In contrast, the Women’s Health
and Aging Study found that high IL-6 levels were an independent
risk factor of CVD mortality among older women [19]. A study of
403 elderly men supported that serum IL-6 was an independent
risk factor of CVD mortality [20]. However, both studies used
gender-specific recruiting strategies which may limit their findings
[19,20]. In our study, we demonstrated that serum IL-6 is an
independent risk factor of CVD mortality in both older men and
women. These results are consistent with published data and
support the potential role of inflammation in the progression of
CVD.
IL-6 has been shown to be an independent prognostic marker in
cancer-specific mortality, including diffuse large-cell lymphoma,
metastatic hormone-refractory prostate cancer, and colorectal
cancer [21–23]. More recently, the PROSPER study showed that
high IL-6 levels was associated with an increased risk for cancer
incidence and cancer-related mortality in 5,804 elderly partici-
pants [24]. However, this study was limited by a short mean
follow-up period of 3.2 years and the inclusion criteria of
preexisting vascular disease or having an increased risk for such
a disease (i.e. smoking, hypertension, diabetes) [24]. In our study,
we demonstrated that IL-6 is an independent risk factor of cancer-
related mortality in older adults with a longer mean follow-up
Table 3. Hazard ratios of all-cause, cardiovascular, cancer, and liver mortality stratified by IL-6 tertiles over 15 years of median
follow-up (excluding individuals with prevalent CVD, cancer, and liver disease).




No. of deaths 978 214 351 413
Unadjusted 1843 Referent 2.02 (1.71–2.40) 2.99 (2.54–3.53) , .0001
Age-sex adjusted 1843 Referent 1.34 (1.13–1.59) 1.80 (1.52–2.13) , .0001
Multivariable adjusted 1841 Referent 1.31 (1.10–1.57) 1.71 (1.44–2.05) , .0001
Multivariable+CRP adjusted 1790 Referent 1.26 (1.06–1.51) 1.53 (1.26–1.85) , .0001
CVD Mortality 323 excluded)
No. of deaths 329 83 103 143
Unadjusted 1520 Referent 1.69 (1.26–2.25) 3.04 (2.31–3.98) , .0001
Age-sex adjusted 1520 Referent 1.09 (0.82–1.47) 1.65 (1.25–2.18) .0002
Multivariable adjusted 1518 Referent 1.06 (0.79–1.43) 1.53 (1.14–2.05) .0030
Multivariable+CRP adjusted 1476 Referent 1.09 (0.80–1.48) 1.52 (1.10–2.10) .0077
Cancer Mortality (447 excluded)
No. of deaths 129 36 41 52
Unadjusted 1396 Referent 1.44 (0.92–2.26) 2.26 (1.47–3.46) .0002
Age-sex adjusted 1396 Referent 1.03 (0.65–1.63) 1.62 (1.04–2.52) .0256
Multivariable adjusted 1395 Referent 0.86 (0.54–1.37) 1.28 (0.81–2.04) .2309
Multivariable+CRP adjusted 1359 Referent 0.72 (0.45–1.16) 0.80 (0.47–1.36) .4469
Liver Disease Mortality (52 excluded)
No. of deaths 20 6 5 9
Unadjusted 1691 Referent 1.03 (0.31–3.39) 2.21 (0.78–6.27) .1314
Age-sex adjusted 1691 Referent 0.74 (0.22–2.50) 1.55 (0.52–4.58) .3786
Multivariable adjusted 1689 Referent 0.64 (0.19–2.19) 1.20(0.38–3.78) .6677
Multivariable+CRP adjusted 1641 Referent 0.58 (0.17–2.01) 0.94 (0.26–3.34) .9927
Statistically significant, when 95% CI does not include 1 (bold).
Multivariate model includes: age, sex, alcohol, BMI, diabetes mellitus, systolic blood pressure, total chol, HDL, smoking.
Multivariate model+CRP includes: age, sex, alcohol, BMI, diabetes mellitus, systolic blood pressure, total chol, HDL, smoking, CRP.
doi:10.1371/journal.pone.0034218.t003
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participants.
However, no previous epidemiological studies have investigated
the association between serum IL-6 and liver-related mortality in a
population-based cohort study. To the best of our knowledge, this
is the first study to show that serum IL-6 is associated with an
increased risk of liver-related in a community-dwelling cohort of
older men and women. Future investigations are needed to fully
elucidate and confirm our findings.
Potential Mechanism
The mechanism underlying the increased risk of liver mortality
with serum IL-6 is unclear. In rodents, IL-6 is a pro-growth factor
required for hepatic regeneration and survival after partial
hepatectomy [25,26]. Sun et al. showed that in vitro IL-6
treatment reduced mortality associated with fatty liver transplants
from alcohol-fed rats [27]. In contrast to its protective effect,
several human and animal studies have demonstrated that IL-6 is
elevated in alcoholic liver disease, NAFLD, NASH, and cirrhosis
[9,11,28,29]. Moreover, IL-6 expression is increased in both
Kupffer cells and hepatocytes with levels correlating to both the
stage of fibrosis and the inflammatory activity in humans with
NASH [11]. Additionally, there is convincing evidence linking IL-
6 to HCC [30,31]. IL-6 induced STAT3 activation via Janus
Kinases (JAK) has been implicated in HCC [32,33].
These findings together suggest that IL-6 is needed acutely for
hepatic protection, regeneration, and survival but chronic
exposure may sensitize the liver to injury and apoptotic cell death.
Although our study cannot test this hypothesis, we believe that
chronic exposure to excess IL-6 levels in the liver may cause
persistent liver damage leading to progressive liver disease, further
increasing the risk of HCC and liver-related mortality. We further
propose that liver and cancer mortality are mediated via CRP
dependent pathways but CVD mortality may not be dependent
upon CRP. Further research is needed to evaluate the mechanisms
of association between IL-6 and cause-specific mortalities.
Limitations and strengths of our Study
First, the Rancho Bernardo cohort consists of relatively healthy,
middle to upper-middle class Caucasians, which limits the
generalizability of our study to other more diverse groups.
However, this was typical of U.S. suburbs in the 1970s when
this community was established. Second, there were few liver-
related deaths based on the death certificates, limiting power to
detect an association between tertiles of IL-6 levels and liver-
related mortality. The literature suggests that using underlying
cause of death alone may grossly underestimate liver mortality
[34,35]. Third, viral hepatitis status was not ascertained; however
among persons 60 years of age and older, the U.S. prevalence of
hepatitis C was 0.9% between 1999 through 2002 [36].
Despite these limitations, the major strengths of our study
include the large sample size, inclusion of both men and women,
prospective study design, detailed evaluation of participants at
baseline, well-characterized covariates, and nearly complete
follow-up for vital status.
Conclusions
In summary, serum IL-6 was a risk factor of all-cause, CVD,
cancer, and liver-related mortality in community-dwelling older
adults. Serum IL-6 was associated with an increased risk of all-
cause and CVD mortality, independent of CRP levels. Our
findings support the important role of chronic inflammation in the
pathogenesis and progression of the two most common causes of
death and advanced liver disease. Additional studies are needed to
determine whether IL-6 may be utilized as a novel prognostic
biomarker for earlier diagnosis and treatment in the future.
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